SEC Form 4 · accession 0001628280-16-021955
Bellerophon Therapeutics, Inc. · BLPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Fabian Tenenbaum
Officer — Chief Executive Officer
Period of report
Dec 7, 2016
Accepted (ET)
Dec 9, 2016 · 4:21 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001600132
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $0.49 | Dec 7, 2016 | A | 1,042,556 | A | — | Dec 6, 2026 | Common Stock | 1,042,556 | 1,042,556 | D |
Explanation of responses
- F1The option grant was approved by Bellerophon Therapeutics, Inc.'s board of directors on December 7, 2016, subject to stockholder approval of an amendment to the stock option plan under which the option was granted.